MedPath

AbbVie's Tavapadon Shows Positive Results in Phase 3 Parkinson's Disease Trial

• AbbVie's tavapadon met its primary endpoint in the TEMPO-2 Phase 3 trial, demonstrating significant improvement in Parkinson's disease symptoms and quality of life. • Patients treated with flexible doses of tavapadon (5-15mg daily) showed a 10.3-point improvement on the MDS-UPDRS scale compared to a 1.2-point worsening in the placebo group. • Tavapadon, which selectively activates D1 and D5 dopamine receptors, is planned for FDA submission next year, marking a potential new treatment option for Parkinson's. • This positive outcome contrasts with recent failures in AbbVie's schizophrenia drug program, highlighting the importance of tavapadon in their pipeline.

AbbVie's tavapadon has demonstrated positive results in a Phase 3 clinical trial for Parkinson's disease. The TEMPO-2 trial evaluated the efficacy of tavapadon in improving symptoms and quality of life for patients with early-stage Parkinson's. The drug, administered in flexible doses ranging from 5 to 15 milligrams daily, met its primary endpoint, showcasing a statistically significant improvement compared to placebo.
The trial results revealed that patients receiving tavapadon experienced a 10.3-point improvement on the MDS-UPDRS (Movement Disorder Society-Unified Parkinson's Disease Rating Scale) after 26 weeks. In contrast, the placebo group showed a 1.2-point worsening on the same scale. This statistically significant difference underscores the potential of tavapadon as a valuable therapeutic option for managing Parkinson's symptoms.
Tavapadon functions as a selective activator of the D1 and D5 dopamine receptors. This mechanism of action differentiates it from existing dopamine therapies and may offer a novel approach to managing Parkinson's disease. The drug has previously demonstrated positive results in other Phase 3 trials, both as a high-dose monotherapy and in combination with existing dopamine therapies.
AbbVie plans to submit tavapadon to the FDA for approval next year. The drug was acquired through AbbVie's purchase of Cerevel Therapeutics. This positive news follows AbbVie's recent setback with emraclidine, an experimental schizophrenia drug that failed in two studies. The success of tavapadon provides a significant boost to AbbVie's pipeline and offers hope for a new treatment option for individuals living with Parkinson's disease.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

JP Morgan 2025: AbbVie's Strategy with Skyrizi and Rinvoq to Compensate for Humira's Decline

AbbVie is focusing on Skyrizi and Rinvoq to offset the impact of Humira's patent expiration. The company also highlights the success of tavapadon in Parkinson’s disease trials and new partnerships for drug development.

Pfizer's Sasanlimab Shows Promise in Bladder Cancer Treatment

Pfizer's sasanlimab, a PD-1 inhibitor, combined with standard therapy, significantly delayed death and disease complications in bladder cancer patients.
The Phase 3 trial results position sasanlimab as a potential competitor to existing immunotherapies like Merck's Keytruda and Bristol Myers Squibb's Opdivo.

FDA Fast-Tracks NeuroVive's Traumatic Brain Injury Drug

The FDA has granted Fast Track designation to NeuroVive's drug, NeuroSTAT, aimed at treating moderate to severe traumatic brain injury (TBI). This status accelerates the drug's development and review process, offering more frequent FDA interactions and feedback. NeuroSTAT works by protecting mitochondria, aiming to prevent secondary brain damage post-TBI, with hopes of improving survival, quality of life, and neurological function. Early trials have shown promising results, including a 35% decrease in brain injury volume in experimental models.

Annovis Bio's Buntanetap Enters Phase 3 for Early Alzheimer's, AbbVie's Tavapadon Shows Promise in Parkinson's

Annovis Bio initiated a Phase 3 trial of buntanetap for early Alzheimer's, aiming to assess both symptomatic and disease-modifying effects over 18 months.
The trial follows positive Phase 2/3 data and has secured initial funding, with plans to enroll over 750 participants across approximately 100 U.S. sites.

Merck Licenses Cancer Drug from LaNova, Tune Therapeutics Advances HBV Therapy, and Amgen Defends Obesity Drug

Merck will license a new cancer drug from LaNova Medicines for $588 million upfront, potentially reaching $2.7 billion in milestone payments, to bolster its oncology portfolio.
Tune Therapeutics is set to initiate human trials in New Zealand for its epigenetic editing therapy targeting hepatitis B virus (HBV), following regulatory clearance.

Pimicotinib Shows Positive Phase 3 Results in Tenosynovial Giant Cell Tumors

Pimicotinib demonstrated a 54% objective response rate at week 25, significantly higher than the 3.2% observed in the placebo group in TGCT patients.
The MANEUVER trial confirmed pimicotinib's potential as a new treatment option by showing statistically significant improvements in patient outcomes, including reduced stiffness and pain.

Abbisko's Pimicotinib Shows Promise in Phase 3 Trial for Tenosynovial Giant Cell Tumor

Pimicotinib, an oral drug developed by Abbisko Therapeutics, demonstrated a 54% tumor shrinkage rate in patients with tenosynovial giant cell tumor (TGCT).
The Phase 3 MANEUVER study evaluated pimicotinib against placebo in patients with TGCT who had not received prior CSF-1R inhibitor treatment.

Annovis Bio's Buntanetap Shows Cognitive Improvement in Parkinson's Subgroup

Annovis Bio's buntanetap demonstrated significant cognitive improvements in Parkinson's patients diagnosed more than three years ago, according to Phase III trial subgroup analysis.
The study highlighted improvements in MDS-UPDRS Part II, Part III, and Phase II+III scores with the 20mg dose of buntanetap compared to placebo.

Annovis Bio's Buntanetap Phase 3 Alzheimer's Trial Streamlined Following FDA Agreement

The FDA has accepted an updated protocol for Annovis Bio's pivotal Phase 3 Alzheimer's disease study, slated to begin in January 2025.
The revised protocol integrates two separate trials into a single 6/18-month trial to assess both symptomatic and disease-modifying effects of buntanetap.

First Participants Randomized in AskBio Phase II Gene Therapy Trial for Parkinson’s Disease

AskBio has announced the randomization of the first participants in its Phase II gene therapy trial targeting Parkinson’s disease, marking a significant step forward in the development of AAV gene therapy technology and therapeutics.

Reference News

[1]
AbbVie drug succeeds in another Parkinson's trial - STAT News
statnews.com · Dec 9, 2024

Terry Pirovolakis developed a gene therapy for his son's ultra-rare disease SPG50 and founded Elpida Therapeutics to hel...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy